Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have received an average recommendation of “Moderate Buy” from the seventeen analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $23.3571.

Several equities research analysts have commented on the stock. Compass Point set a $25.00 target price on shares of Compass Pathways in a research note on Tuesday, July 7th. Raymond James Financial restated a “buy” rating on shares of Compass Pathways in a research report on Friday, May 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Compass Pathways in a research note on Friday, July 17th. Wolfe Research reiterated an “outperform” rating on shares of Compass Pathways in a report on Tuesday, July 7th. Finally, HC Wainwright decreased their target price on Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Friday, August 7th.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of CMPS. EverSource Wealth Advisors LLC grew its holdings in shares of Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after buying an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd bought a new stake in Compass Pathways in the fourth quarter valued at approximately $38,000. Parallel Advisors LLC increased its holdings in shares of Compass Pathways by 8,450.6% during the 1st quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock worth $40,000 after acquiring an additional 7,183 shares during the last quarter. Advisory Services Network LLC bought a new stake in Compass Pathways in the 3rd quarter valued at $41,000. Finally, North Star Investment Management Corp. raised its stake in Compass Pathways by 1,354.0% in the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock valued at $42,000 after acquiring an additional 7,000 shares during the period. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Price Performance

CMPS opened at $13.27 on Friday. The company has a fifty day moving average price of $13.10 and a two-hundred day moving average price of $10.34. The firm has a market capitalization of $1.84 billion, a PE ratio of -2.87 and a beta of 2.54. Compass Pathways has a 52 week low of $4.82 and a 52 week high of $15.40. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). As a group, analysts anticipate that Compass Pathways will post -1.26 earnings per share for the current year.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.